Pulmonary preneoplasia - Sequential molecular carcinogenetic events

Histopathology

Volumn 54, Issue 1, 2009, Pages 43-54

  Lantuéjoul, Sylvie ^a,b   Salameire, Dimitri ^a   Salon, Caroline ^a   Brambilla, Elisabeth ^a  

^a UNIV GRENOBLE ALPES   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

Atypical adenomatous hyperplasia; Dysplasia; Lung cancer; Molecular pathology; Preneoplasia

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TUMOR MARKER; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CELL IMMORTALIZATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; LUNG DYSPLASIA; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; HUMANS; LUNG; LUNG NEOPLASMS; PRECANCEROUS CONDITIONS; SMALL CELL LUNG CARCINOMA;

NICOTIANA TABACUM;

EID: 58449090634     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03182.x     Document Type: Review

References (90)

1. Surveillance Epidemiology and End Result (SEER) statistics. Available at http://seer.cancer.gov.
2. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu. Rev. Med. 2003 54 73 87.
3. Khuder SA. Effect of cigarette smoking on major histological subtypes of lung cancer: meta-analysis. Lung Cancer 2001 31 139 148.
4. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 2003 3 733 744.
5. Amos CI, Xu W, Spitz MR. Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res. 1999 151 3 12.
6. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 2007 28 507 518.
7. Paz-Elizur T, Sevilya Z, Leitner-Dagan Y, Elinger D, Roisman LC, Livneh Z. DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention. Cancer Lett. 2008 266 60 72.
8. Thorgeirsson TE, Geller F, Sulem P et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008 452 b638 b642.
9. Hung RJ, McKay JD, Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008 452 633 637.
10. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Eds. WHO classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon : IARC Press, 2004.
11. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N. Engl. J. Med. 1979 300 381 385.
12. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res. 1994 13 561 568.
13. Jeanmart M, Lantuejoul S, Fievet F et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin. Cancer Res. 2003 9 2195 2203.
14. George JP, Banerjee AK, Read CA et al. Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax 2007 6 43 50.
15. Lam S, Keneddy T, Unger M et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998 113 696 702.
16. Lam S, MacAulay C, Hung J, LeRiche J, Profio AE, Palcic B. Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscope device. J. Thorac. Cardiovasc. Surg. 1993 105 1035 1040.
17. Moro-Sibilot D, Jeanmart M, Lantuejoul S et al. Cigarette smoking, preinvasive bronchial lesions, and autofluorescence bronchoscopy. Chest 2002 122 1902 1908.
18. Amin MB, Tamboli P, Merchant SH et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am. J. Surg. Pathol. 2002 26 358 364.
19. Chapman KD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br. J. Cancer 2000 83 632 636.
20. Suzuki K, Nagai K, Yoshida J et al. The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer 1997 79 1521 1526.
21. Walch AK, Zitzelsberger HF, Aubele MM et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am. J. Pathol. 1998 153 1089 1098.
22. Debelenko LV, Brambilla E, Agarwal SK. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum. Mol. Genet. 1997 6 2285 2290.
23. Davies SJ, Gosney JR, Hansell DM et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 2007 62 248 252.
24. Fessler MB, Cool CD, Miller YE, Schwarz MI, Brown KK. Idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells in a patient with acromegaly. Respirology 2004 9 274 277.
25. Nicholson AG, Perry LJ, Cury PM et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation. Histopathology 2001 38 202 208.
26. Breuer RH, Pasic A, Smit EF et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin. Cancer Res. 2005 11 537 543.
27. Knudson AG. Hereditary cancers disclose a class of cancer genes. Cancer 1989 63 1888 1891.
28. Croce CM. Oncogenes and cancer. N. Engl. J. Med. 2008 358 502 511.
29. Zochbauer-Muller S, Minna JD. The biology of lung cancer including potential clinical applications. Chest Surg. Clin. N. Am. 2000 10 691 708.
30. Wistuba II, Behrens C, Virmani AK et al. High resolution chromosome 3p allelotyping of human cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000 60 1949 1960.
31. Salaün M, Sesboüé R, Moreno-Swirc S et al. Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. Am. J. Respir. Crit. Care Med. 2008 177 880 886.
32. Takamochi K, Ogura T, Suzuki K et al. Loss of heterozygosity on chromosome 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am. J. Pathol. 2001 159 1941 1948.
33. Sozzi G, Veronese ML, Negrini M et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996 85 17 26.
34. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008 27 1863 74.
35. Dammann R, Li C, Yoon JH et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat. Genet. 2000 25 315 319.
36. Cheung AL, Si HX, Wang LD, An JY, Tsao SW. Loss of heterozygosity analyses of esophageal squamous cell carcinoma and precursor lesions from a high incidence area in China. Cancer Lett. 2006 (Epub ahead of print).
37. Lantuejoul S, Constantin B, Drabkin H et al. VEGF, Semaphorin SEMA3F and their common receptors neuropilins NP1 and NP2 expressions in preinvasive bronchial lesions, lung tumors and cell lines. J. Pathol. 2003 2000 336 347.
38. Kurie JM, Lotan R, Lee JJ et al. Treatment of former smokers with 9-cis-retinoic acid reverse loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl. Cancer Inst. 2003 95 206 214.
39. Martinet N, Alla F, Farre G et al. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Res. 2000 60 2869 2875.
40. Sharp TV, Munoz F, Bourboulia D et al. LIM domains-containing protein 1 (LIMD1), a tumour suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc. Natl. Acad. Sci. U.S.A. 2004 101 16531 16536.
41. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002 21 6877 6883.
42. Jonsson S, Varella-Garcia M, Miller YE et al. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am. J. Respir. Crit. Care Med. 2008 177 342 347.
43. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microstaellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. U.S.A. 1994 91 9871 9875.
44. Miozzo M, Sozzi G, Musso K et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 1996 56 2285 2288.
45. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 2004 55 433 457.
46. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 2002 29 3 14.
47. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 1497 1500.
48. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004 101 13306 13311.
49. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004 350 2129 2139.
50. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005 97 643 655.
51. Yoshida Y, Shibata T, Kokubu A et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005 50 1 8.
52. Tang X, Shigematsu H, Bekele BN et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005 65 7568 7572.
53. Merrick DT, Kittelson J, Winterhalder R et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin. Cancer Res. 2006 12 2281 2288.
54. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancer. Int. J. Cancer 2006 118 257 262.
55. Sakamoto H, Shimizu J, Horio Y et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J. Pathol. 2007 212 287 294.
56. Marchetti A, Buttitta F, Pellegrini S et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J. Pathol. 1996 179 254 259.
57. Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF. K-ras mutations are relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 1994 54 5811 5815.
58. Pao W, Wang TY, Riely GJ et al. Kras mutations and primary resistance of lung adenocarcinoma to gefitinib or erlotinib. PLoS Med. 2005 2 e17.
59. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001 61 3986 3997.
60. Massion PP, Taflan PM, Shyr Y et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 2004 170 1088 1094.
61. Richardson GE, Johnson BE. The biology of lung cancer. Semin. Oncol. 1993 20 105 127.
62. Gazzeri S, Brambilla E, Caron de Fromentel C et al. p53 genetic abnormalities and myc activation in human lung carcinoma. Int. J. Cancer 1994 58 24 32.
63. Tsou JA, Hagen JA, Carpentier CL, Laird-Offringa iA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002 21 5450 5461.
64. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000 60 5954 5958.
65. Hainaut P, Pfeifer GP. Patterns of p53 G - >T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001 22 367 374.
66. Brambilla E, Gazzeri S, Lantuejoul S et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin. Cancer Res. 1998 4 1609 1618.
67. Tominaga M, Sueoka N, Irie K et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hmRNP B1, combined with cell-cycle related markers p16, cyclin D1, and Ki67. Lung Cancer 2003 40 45 53.
68. Ponticiello A, Barra E, Giani E, Bocchino M, Sanduzzi A. p53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study. Eur. Respir. J. 2000 15 547 552.
69. ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002 21 2750 2761.
70. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 1998 16 497 504.
71. Baryshnikova E, Destro A, Infante MV et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin. Cancer Res. 2008 14 1913 1919.
72. Hsu HS, Chen TP, Wen CK et al. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J. Pathol. 2007 213 412 419.
73. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin. Cancer Res. 1999 5 243 450.
74. Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelium of patients with lung cancer is associated with smoking and predicts survival. J. Clin. Oncol. 2003 21 2085 2093.
75. Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorogenesis. Nature 2005 434 864 870.
76. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005 434 907 913.
77. Nuciforo PG, Luise C, Capra M, Pelosi G, d'Adda di Fagagna F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007 28 2082 2088.
78. Olaussen KA, Dunant A, Fouret P et al. IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006 355 983 991.
79. Hiyama K, Hiyama E, Ishioka S et al. Telomerase activity in small cell and non small cell lung cancer. J. Natl. Cancer Inst. 1995 87 895 902.
80. Lantuejoul S, Soria JC, Moro-Sibilot D et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br. J. Cancer 2004 90 1222 1229.
81. Marchetti A, Bertacca G, Buttitta F et al. Telomerase activity as a prognostic indicator in stage I non small cell lung cancer. Clin. Cancer Res. 1999 5 2077 2081.
82. Xinarianos G, Scott FM, Liloglou T et al. Telomerase activity in non-small cell lung carcinomas correlates with smoking status. Int. J. Oncol. 1999 15 961 965.
83. Nakanishi K, Kawai T, Kumaki F et al. Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum. Pathol. 2002 33 697 702.
84. Lantuejoul S, Soria JC, Morat L et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin. Cancer Res. 2005 11 2074 2082.
85. Decaussin M, Sartelet H, Robert C et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J. Pathol. 1999 188 369 377.
86. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998 92 735 745.
87. Brambilla E, Constantin B, Drabkin H, Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and migration. Am. J. Pathol. 2000 156 939 950.
88. Kawakami T, Tokunaga T, Hatanaka H et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in non-small cell lung carcinoma. Cancer 2002 95 2196 2201.
89. Keith RL, Miller YE, Gemmill RM et al. Angiogenic squamous dysplasia in bronchi of individuals at high-risk for lung cancer. Clin. Cancer Res. 2000 6 1616 1625.
90. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am. J. Surg. Pathol. 2005 29 633 639.